Armisarte 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0033 
Minor change in labelling or package leaflet not 
16/10/2023 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IG/1612 
A.1 - Administrative change - Change in the name 
31/05/2023 
11/08/2023 
SmPC, 
and/or address of the MAH 
Labelling and 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
II/0030/G 
This was an application for a group of variations. 
23/03/2023 
n/a 
PL 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0031 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
18/01/2023 
11/08/2023 
SmPC, 
storage conditions of the finished product - Other 
variation 
Labelling and 
PL 
IB/0029 
C.I.2.a - Change in the SPC, Labelling or PL of a 
24/08/2022 
11/08/2023 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II and PL 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/2330/
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
202102 
pemetrexed 
IB/0027 
C.I.z - Changes (Safety/Efficacy) of Human and 
03/08/2021 
01/07/2022 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IAIN/0028 
B.II.b.1.a - Replacement or addition of a 
02/08/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0024 
B.II.f.1.z - Stability of FP - Change in the shelf-life or 
29/06/2021 
01/07/2022 
SmPC, 
To include the dilution of Pemetrexed 25 mg/mL 
storage conditions of the finished product - Other 
Labelling and 
concentrate for solution for infusion in 0.9% sodium 
variation 
PL 
chloride to maintain the dilution stable for 24 hours at 25oC 
and 7 days at 2oC - 8oC. 
IA/0026 
B.II.e.6.b - Change in any part of the (primary) 
08/06/2021 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IAIN/0023 
B.II.b.1.a - Replacement or addition of a 
22/04/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
R/0022 
Renewal of the marketing authorisation. 
25/06/2020 
13/08/2020 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Armisarte in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IB/0021 
B.II.f.1.a.3 - Stability of FP - Reduction of the shelf 
26/03/2020 
13/08/2020 
SmPC and PL 
life of the finished product - After dilution or 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
reconstitution 
IA/0020 
B.I.b.1.d - Change in the specification parameters 
17/03/2020 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
PSUSA/2330/
Periodic Safety Update EU Single assessment - 
18/10/2018 
15/01/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
201802 
pemetrexed 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2330/201802. 
IB/0019 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
18/12/2018 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
II/0017/G 
This was an application for a group of variations. 
13/09/2018 
n/a 
B.II.d.1.f - Change in the specification parameters 
and/or limits of the finished product - Deletion of a 
specification parameter which may have a significant 
effect on the overall quality of the finished product 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
IAIN/0016 
C.I.z - Changes (Safety/Efficacy) of Human and 
10/04/2018 
15/01/2019 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/10/2017 
25/05/2018 
SmPC, 
generic/hybrid/biosimilar products following 
Labelling and 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PL 
IA/0015 
B.II.b.2.a - Change to importer, batch release 
28/09/2017 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IAIN/0013 
B.II.b.2.c.1 - Change to importer, batch release 
28/09/2017 
25/05/2018 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0008/G 
This was an application for a group of variations. 
18/05/2017 
25/05/2018 
SmPC, 
Labelling and 
PL 
B.II.a.3.b.2 - Changes in the composition 
(excipients) of the finished product - Other excipients 
- Qualitative or quantitative changes in one or more 
excipients that may have a significant impact on the 
safety, quality or efficacy of the product 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
IA/0011 
A.4 - Administrative change - Change in the name 
05/04/2017 
n/a 
and/or address of a manufacturer or an ASMF holder 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0009/G 
This was an application for a group of variations. 
25/01/2017 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.e.4.c - Change in shape or dimensions of the 
container or closure (immediate packaging) - Sterile 
medicinal products 
IB/0007 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
05/01/2017 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0006/G 
This was an application for a group of variations. 
21/09/2016 
n/a 
B.II.b.1.f - Replacement or addition of a 
manufacturing site for part or all of the 
manufacturing process of the FP - Site where any 
manufacturing operation(s) take place, except batch 
release, batch control, and secondary packaging, for 
sterile medicinal products (including those that are 
aseptically manufactured) excluding biological/ 
immunological medicinal products 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.4.z - Change in the batch size (including batch 
size ranges) of the finished product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
B.II.e.4.c - Change in shape or dimensions of the 
container or closure (immediate packaging) - Sterile 
medicinal products 
B.II.e.6.b - Change in any part of the (primary) 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
N/0005 
Update of the package leaflet with revised contact 
20/06/2016 
16/02/2017 
PL 
details of the local representatives for Belgium, the 
Netherlands and Portugal. In addition, the MAH took 
the opportunity to make linguistic corrections in the 
Danish, German, Greek, Finnish, Hungarian, 
Icelandic, Italian, Latvian, Maltese, Dutch, 
Norwegian, Portuguese and Swedish labelling and 
package leaflets in line with the EN text. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0003 
B.II.f.1.b.3 - Stability of FP - Extension of the shelf 
11/03/2016 
16/02/2017 
SmPC and PL 
life of the finished product - After dilution or 
reconstitution (supported by real time data) 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
IB/0002 
C.I.z - Changes (Safety/Efficacy) of Human and 
19/02/2016 
16/02/2017 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IAIN/0001 
A.2.a - Administrative change - Change in the 
10/02/2016 
16/02/2017 
SmPC, 
(invented) name of the medicinal product for CAPs 
Labelling and 
PL 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
